Medical Device News Magazine

Three Lakes Foundation and Mayo Clinic Colloboration Will Help Increase Awareness of Pulmonary Fibrosis Symptoms

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

February 2, 2021

Three Lakes Foundation and Mayo Clinic collaboration will allow an increase in awareness of pulmonary fibrosis symptoms; improve an understanding of the current diagnostic journey, and develop a remote diagnostic tool that connects patients with appropriate healthcare resources at an earlier and more treatable phase of their illness.

“Our collaboration with Mayo Clinic is critical,” said Dana Ball, executive director of Three Lakes Foundation. “Finding symptomatic individuals and improving time to diagnosis will provide the opportunity to intervene earlier in the diagnostic process, leading to preservation of health and earlier treatment of lung fibrosis.”

Pulmonary Fibrosis is a progressive and fatal lung disease that occurs when lung tissue becomes damaged and scarred. As the condition worsens, patients have difficulty breathing and ultimately needing supplemental oxygen to live. PF can be difficult to diagnose because the symptoms are similar to other conditions, such as allergies, bronchitis, asthma and even chronic obstructive pulmonary disease (COPD). By the time most patients receive an accurate diagnosis, their lung capacity has already deteriorated significantly. Each year, approximately 40,000 people die from Pulmonary Fibrosis.

The research initiative will be led by Andrew Limper, MD, who is associate dean of practice transformation and Annenberg professor of pulmonary medicine at the Mayo Clinic.

According to Dr. Limper, the research will address three objectives:

  • To improve current time to diagnosis and identify the barriers that lead to accurate diagnoses by leveraging Mayo Clinic’s rich clinical data
  • Use artificial intelligence and data analytics to further define the Pulmonary Fibrosis diagnostic journey, the prevalence of misdiagnoses, and clinical clues to PF
  • Synthesize above data points to develop a prototype for remote diagnosis

“There are currently two FDA-approved therapies for PF that slow disease progression,” said Cheryl Nutter-Nickerson, VP of research and development for Three Lakes Foundation. “Additionally, there are currently more than 30 ongoing clinical trials for Pulmonary Fibrosis. The path to stopping disease progression and preserving quality of life may be closer than we think. Being able to diagnose Pulmonary Fibrosis early has never been more important.”

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.